Benjamin Tomlinson
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Benjamin Tomlinson sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Benjamin Tomlinson: 4 sponsored US clinical trials, 2 recruiting.
Benjamin Tomlinson sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 2 trials.
Upper-quartile sponsor footprint
Benjamin Tomlinson sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
NCT06129734
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
NCT04187703
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
NCT04732845
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
NCT03434769
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
What is open in the Benjamin Tomlinson pipeline
2 recruiting of 4 indexed (50% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Non-Hodgkin Lymphoma (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Benjamin Tomlinson: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Benjamin Tomlinson sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Benjamin Tomlinson page
4 registered trials is a research-attention snapshot, not an endorsement of Benjamin Tomlinson or any single study.
- 2 of Benjamin Tomlinson's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Hodgkin Lymphoma is the condition Benjamin Tomlinson studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Benjamin Tomlinson pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.